Midostaurin

Drug Profile

Midostaurin

Alternative Names: 4-N-benzoyl staurosporine; Benzoylstaurosporine; CGP 41251; N-benzoyl-staurosporine; PKC412; PKC412A; Rydapt

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University Comprehensive Cancer Center
  • Class Antineoplastics; Carbazoles; Eye disorder therapies; Indole alkaloids; Skin disorder therapies; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Multidrug resistance-associated protein inhibitors; Platelet-derived growth factor receptor antagonists; Protein kinase C inhibitors; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Systemic mastocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia; Systemic mastocytosis
  • Discontinued Acute lymphoblastic leukaemia; Colorectal cancer; Diabetic macular oedema; Gastrointestinal stromal tumours; Multiple myeloma

Most Recent Events

  • 21 Jul 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of midostaurin for Acute myeloid leukaemia (First-line therapy) in European Union
  • 21 Jul 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of midostaurin for Systemic mastocytosis in European Union
  • 14 Jul 2017 Novartis plans the phase I/II HOVON 148 AML trial for Acute myeloid leukaemia (In adults, In the elderly, Combination therapy, Prevention) in the Netherlands (NTR6511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top